# A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

> **NCT05819684** · PHASE1 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 133 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SHR-4602 for injection

## Key facts

- **NCT ID:** NCT05819684
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-18
- **Primary completion:** 2025-05-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 133 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05819684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05819684, "A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05819684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*